WebNov 30, 2024 · Using the company’s artificial intelligence (AI) drug discovery platform, BioXcel has identified BXCL502 for the chronic treatment of agitation. It is a potent and … WebNov 30, 2024 · In May 2024, BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced that the New Drug Application (NDA) for BXCL501 for the treatment of schizophrenia and …

BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to ...

WebNov 10, 2024 · Net Loss: BioXcel Therapeutics reported a net loss of $41.8 million for the third quarter of 2024, compared to a net loss of $26.8 million for the same period in 2024. The Company used $31.5 ... WebApr 6, 2024 · First and only FDA-approved orally dissolving sublingual film for mild, moderate or severe agitation in patients with schizophrenia or bipolar I or II disorder 1. IGALMI demonstrated onset of action as early as 20 minutes and high response rate with both 120 mcg and 180 mcg doses in pivotal studies 1. Up to 25 million agitation episodes … gray suit yellow tie

Investor Relations BioXcel Therapeutics

WebDec 15, 2024 · BXCL501 is an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of agitation associated with... WebMar 10, 2024 · We initiated formulation for BXCL502 for the chronic treatment of agitation in dementia patients. 502 is designed to be a potent and selective antagonist for a GPCR target affecting serotonergic... WebJan 3, 2024 · Its pipeline product portfolio comprises BXCL501, an adrenergic agent with a sublingual route of administration is used for treating neuropsychiatric and neurodegenerative diseases; BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers; and BXCL502, a novel approach to the … cholesterin 252